Receptor tyrosine kinase
signalling as a target for cancer intervention strategies.
AXL, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase
Although substantial traction has been gained in recent years by incorporating well-validated predictive biomarkers into the drug development process [for example, targeting anaplastic lymphoma receptor tyrosine kinase
(ALK)-positive non--small cell lung cancer with ALK inhibitors and targeting b-raf proto-oncogene, serine/threonine kinase (BRAF) mutant melanoma with BRAF inhibitors], this positive trend is likely to reach a plateau unless we develop better preclinical cancer models, target validation, and clinical trials incorporating novel predictive biomarkers that provide early signals of treatment efficacy or failure.
Expression of the receptor tyrosine kinase
genes, Ror1 and Ror2, during mouse development.
These data suggest a way in which receptor tyrosine kinase
inhibitors could be used to treat individuals with KRAS mutant colorectal cancers.
Vande tanib, for example, is a potent inhibitor of VEGF and epidermal growth factor receptor tyrosine kinases
as well as re arranged-during-transfection (RET) tyrosine kinases, while XL184 inhibits RET, VEGF receptor, and MET tyrosine kinases.
ARQ 197 mediates its effects by inhibiting the activity of c-Met, a receptor tyrosine kinase
that plays multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis.
Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase
EphB4 is a receptor tyrosine kinase
that is expressed on epithelial cells during fetal life.
Lenvima is an orally available multiple receptor tyrosine kinase
(RTK) inhibitor that was discovered by Eisai.
The topics include mitochondrial gene expression: a playground of evolutionary tinkering, the mechanics and single-molecule interrogation of DNA recombination, mechanisms of bacterial transcription termination: all good things must end, the biosynthesis of the metalloclusters of nitrogenases, the spatial and temporal regulation of receptor tyrosine kinase
activity and intracellular signal transduction, experimental milestones in the discovery of molecular chaperones as polypeptide unfolding enzymes, and reactive oxygen species and neutrophil function.
Recent guidelines from International Association for the Study of Lung Cancer/Association for Molecular Pathology/College of American Pathologists recommend at minimum EGFR and anaplastic lymphoma receptor tyrosine kinase
(ALK) testing on all tumors with adenocarcinoma histology (including adenosquamous, adeno--small cell neuroendocrine, and poorly differentiated) (1).